What is the total amount Zydus Lifesciences will pay to Astellas Pharma?

Zydus Lifesciences will pay $120 million to Astellas Pharma as part of a settlement, along with per-unit licensing fees.

What is the Mirabegron patent dispute about?

The patent dispute is over Astellas Pharma's bladder disorder drug, Mirabegron, involving Zydus Lifesciences and its generic version.

Did other companies also settle with Astellas Pharma regarding Mirabegron?

Yes, Lupin, another Indian drugmaker, also settled its dispute with Astellas Pharma over the same drug for $90 million.

Home / Business and Economy / Zydus Pays $120M to Settle Bladder Drug Patent Dispute

Zydus Pays $120M to Settle Bladder Drug Patent Dispute

12 Feb

•

Summary

Zydus Lifesciences will pay $120 million to Astellas Pharma.
The settlement resolves a patent dispute over the drug Mirabegron.
Zydus will also pay licensing fees on generic Mirabegron sales.

Zydus Pays $120M to Settle Bladder Drug Patent Dispute

Zydus Lifesciences, an Indian pharmaceutical company, and its U.S. subsidiary have reached a settlement with Astellas Pharma, paying $120 million to resolve a patent dispute. The legal conflict centered on Astellas's bladder disorder drug, Mirabegron.

As part of the agreement, Zydus will pay an initial $120 million settlement fee. Additionally, the company will provide a pre-paid per-unit licensing fee on its generic Mirabegron sales in the United States, effective until September 2027.

This settlement permits Zydus to continue marketing its generic version of Mirabegron within the U.S. market. The specifics of the agreement beyond these financial terms remain confidential between the two companies.